Search

Colloidal oatmeal

Colloidal oatmeal is produced by grinding fine granules of oatmeal and boiling it to extract the colloidal material. … Colloidal oatmeal is a FDA-approved skin protectant that temporarily protects and helps relieve minor skin irritation and itching due to rashes, eczema, poison ivy, oak, sumac, or insect bites.

Ustekinumab

In October 2019, it was also approved by the FDA for use to manage moderately to severely active ulcerative colitis in adults. … In September 2016, ustekinumab was additionally approved for the management of moderate to severe Crohn's disease in selected adult patients.

Aflibercept

the FDA as treatments for retinal diseases; Enzeevi (aflibercept-abzv)[L53053], approved in August 2024, was also approved by the FDA for similar indications. … [L47966,L47971] The intravitreal formulation, under the brand name EYELEA, was approved by the FDA for the treatment of retinopathy of prematurity in preterm infants in February 2023 and for the treatment

Tenecteplase

Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 1...

Colistin

Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally. … It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes.

Luspatercept

[A187829,L42455] It was first approved for use in the United States in November 2019 under the brand name Reblozyl® for the treatment of anemia in patients with beta thalassemia who require regular blood … Luspatercept is a recombinant fusion protein comprised of a modified extracellular domain of activin receptor type IIB fused to the FC domain of human IgG1.

Methylprednisolone aceponate

Methylprednisolone

Methylprednisolone is a prednisolone derivative glucocorticoid with higher potency than prednisone. It was first described in the literature in the late 1950s. Methylprednisolone was granted FDA approval on 24 October 1957. In the outbre...

Tirzepatide

Dual GIP/GLP-1 agonists gained increasing attention as new therapeutic agents for glycemic and weight control as they demonstrated better glucose control and weight loss compared to selective GLP-1 receptor … agonist for this indication.

Alirocumab

Alirocumab is a biopharmaceutical that obtained FDA approval in July 2015 as a second line treatment for high cholesterol in adults whose LDL-cholesterol (LDL-C) is not controlled by the combination of … From this family, it was the first agent to receive FDA approval. The FDA approval was contingent on the completion of further clinical trials to better determine efficacy and safety.